Mesoblast (MEOBF) Non-Current Deffered Revenue (2015 - 2026)
Mesoblast's (MEOBF) quarterly Non-Current Deffered Revenue came in at $2.5 million in Q2 2026, little changed year-over-year from $2.5 million in Q2 2025, and little changed quarter-over-quarter from $2.5 million in Q4 2025.
Analysis
Mesoblast (MEOBF) Non-Current Deffered Revenue (2015 - 2026) Analysis & Trends
Mesoblast has disclosed Non-Current Deffered Revenue across 11 years of filings, most recently posting $2.5 million for Q2 2026.
- In Q2 2026, Non-Current Deffered Revenue changed 0.0% year-over-year to $2.5 million; the TTM figure through Jun 2026 stood at $2.5 million (changed 0.0% YoY), while the FY2026 annual figure was $2.5 million, changed 0.0% from the prior year.
- Non-Current Deffered Revenue came in at $2.5 million for Q2 2026 at Mesoblast, roughly flat from $2.5 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $2.5 million in Q1 2022 to a low of $2.5 million in Q1 2022.
- Average Non-Current Deffered Revenue over 5 years is $2.5 million, with a median of $2.5 million recorded in 2022.
- The largest YoY upside for Non-Current Deffered Revenue was 0.0% in 2022 against a maximum downside of 0.0% in 2022.
- Over 5 years, Non-Current Deffered Revenue stood at $2.5 million in 2022, then changed by 0.0% to $2.5 million in 2023, then changed by 0.0% to $2.5 million in 2024, then changed by 0.0% to $2.5 million in 2025, then changed by 0.0% to $2.5 million in 2026.
- Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $2.5 million in Q2 2026, $2.5 million in Q4 2025, and $2.5 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | - |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 110.13 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | - |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | 2.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.50 Mn |
| Dec 31, 2025 | 2.50 Mn |
| Jun 30, 2025 | 2.50 Mn |
| Dec 31, 2024 | 2.50 Mn |
| Jun 30, 2024 | 2.50 Mn |
| Dec 31, 2023 | 2.50 Mn |
| Jun 30, 2023 | 2.50 Mn |
| Mar 31, 2023 | 2.50 Mn |
| Dec 31, 2022 | 2.50 Mn |
| Sep 30, 2022 | 2.50 Mn |
| Jun 30, 2022 | 2.50 Mn |
| Mar 31, 2022 | 2.50 Mn |
| Dec 31, 2021 | 2.50 Mn |
| Sep 30, 2021 | 2.50 Mn |
| Jun 30, 2021 | 2.50 Mn |
| Mar 31, 2021 | 2.50 Mn |
| Dec 31, 2020 | 2.50 Mn |
| Sep 30, 2020 | 2.50 Mn |
| Jun 30, 2020 | 2.50 Mn |
| Mar 31, 2020 | 2.50 Mn |